These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
177 related items for PubMed ID: 19207032
21. The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis. Machaj F, Rosik J, Szostak B, Malinowski D, Safranow K, Olędzka G, Wiechec E, Pawlik A. Clin Rheumatol; 2023 Sep; 42(9):2477-2483. PubMed ID: 37289314 [Abstract] [Full Text] [Related]
23. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A. Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742 [Abstract] [Full Text] [Related]
24. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis. Wiacek R, Kolossa K, Jankowski T, Jeka S, Karmowski A, Karmowski M, Gworys B. Adv Clin Exp Med; 2012 Mar; 21(3):337-42. PubMed ID: 23214197 [Abstract] [Full Text] [Related]
25. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, Strand V. Arthritis Rheum; 1999 Jul; 42(7):1322-8. PubMed ID: 10403258 [Abstract] [Full Text] [Related]
26. Patterns of angiotensin converting enzyme insertion/deletion gene polymorphism among an Egyptian cohort of patients with rheumatoid arthritis. Ahmed AZ, El-Shahaly HA, Omar AS, Ghattas MH. Int J Rheum Dis; 2013 Jun; 16(3):284-90. PubMed ID: 23981749 [Abstract] [Full Text] [Related]
27. Leflunomide in Pakistani patients with rheumatoid arthritis: prospective study in daily rheumatology practice. Ahmad NM, Farman S, Saeed MA, Hameed R, Umair M, Ghafoor E. Int J Rheum Dis; 2011 Feb; 14(1):48-54. PubMed ID: 21303481 [Abstract] [Full Text] [Related]
28. Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis. Yu X, Wang L, Xu P, Lu W, Lan G, Ping L, Wang X, Tian J, Liu J. J Rheumatol; 2012 Jun; 39(6):1171-8. PubMed ID: 22505700 [Abstract] [Full Text] [Related]
29. Immunosuppressive agent leflunomide: a SWNTs-immobilized dihydroortate dehydrogenase inhibitory effect and computational study of its adsorption properties on zigzag single walled (6,0) carbon and boron nitride nanotubes as controlled drug delivery devices. Raissi H, Mollania F. Eur J Pharm Sci; 2014 Jun 02; 56():37-54. PubMed ID: 24566615 [Abstract] [Full Text] [Related]
30. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C. Chin Med J (Engl); 2003 Aug 02; 116(8):1228-34. PubMed ID: 12935395 [Abstract] [Full Text] [Related]
31. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R. Indian J Med Res; 2006 Nov 02; 124(5):521-6. PubMed ID: 17213520 [Abstract] [Full Text] [Related]
32. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Van Roon EN, Jansen TL, Mourad L, Houtman PM, Bruyn GA, Griep EN, Wilffert B, Tobi H, Brouwers JR. Br J Clin Pharmacol; 2004 Jun 02; 57(6):790-7. PubMed ID: 15151525 [Abstract] [Full Text] [Related]
33. The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity. Hopkins AM, O'Doherty CE, Foster DJ, Suppiah V, Upton RN, Spargo LD, Cleland LG, Proudman SM, Wiese MD. J Clin Pharm Ther; 2014 Oct 02; 39(5):555-60. PubMed ID: 25040563 [Abstract] [Full Text] [Related]
34. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Flendrie M, Creemers MC, Welsing PM, van Riel PL. Rheumatology (Oxford); 2005 Apr 02; 44(4):472-8. PubMed ID: 15598707 [Abstract] [Full Text] [Related]
35. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, Lee JH, Yoo WH, Lee SI. Scand J Rheumatol; 2009 Apr 02; 38(1):11-4. PubMed ID: 19191187 [Abstract] [Full Text] [Related]
36. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V. Arthritis Rheum; 2001 Sep 02; 44(9):1984-92. PubMed ID: 11592358 [Abstract] [Full Text] [Related]
37. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM. J Rheumatol; 2008 Apr 02; 35(4):562-71. PubMed ID: 18322994 [Abstract] [Full Text] [Related]
38. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, Thompson A, Wells G. Arthritis Rheum; 1999 Sep 02; 42(9):1870-8. PubMed ID: 10513801 [Abstract] [Full Text] [Related]
39. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Seitz M, Wirthmüller U, Möller B, Villiger PM. Rheumatology (Oxford); 2007 Jan 02; 46(1):93-6. PubMed ID: 16720636 [Abstract] [Full Text] [Related]
40. The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study. Muehler A, Kohlhof H, Groeppel M, Vitt D. Drugs R D; 2019 Dec 02; 19(4):351-366. PubMed ID: 31621054 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]